NASDAQ:IBB - iShares NASDAQ Biotechnology Index Stock Price, Price Target & More

Sign in or create an account to add this stock to your watchlist.
$112.23 -0.38 (-0.34 %)
(As of 06/22/2018 04:00 PM ET)
Previous Close$112.61
Today's Range$111.69 - $112.88
52-Week Range$100.22 - $119.30
Volume2.43 million shs
Average Volume2.81 million shs
Market Capitalization$9.17 billion
P/E RatioN/A
Dividend Yield0.37%
Beta1.34
iShares NASDAQ Biotechnology Index logoiShares Nasdaq Biotechnology ETF (the Fund), formerly iShares Nasdaq Biotechnology Index Fund, is an exchange-traded fund (ETF). The Fund seeks investment results that correspond generally to the price and yield performance of the NASDAQ Biotechnology Index (the Index). The Index contains securities of NASDAQ listed companies that are classified according to the Industry Classification Benchmark as either biotechnology or pharmaceuticals, which also meet other eligibility criteria determined by NASDAQ. The Fund invests in a representative sample of securities included in the Index that collectively has an investment profile similar to the Index. Due to the use of representative sampling, the Fund may or may not hold all of the securities that are included in the Index. The Fund’s investment advisor is BlackRock Fund Advisors, which is indirectly owned by BlackRock, Inc.

Receive IBB News and Ratings via Email

Sign-up to receive the latest news and ratings for IBB and its competitors with MarketBeat's FREE daily newsletter.

Basic Details

Issuer Blackrock
Fund NameiShares Nasdaq Biotechnology ETF
Tax ClassificationRegulated Investment Company
SymbolNASDAQ:IBB
Inception Date2/5/2001
Fund ManagerDiane Hsiung, Jennifer Hsui, Greg Savage, Alan Mason
WebN/A
PhoneN/A

Fund Focus

Asset ClassEquity
BenchmarkNASDAQ Biotechnology TR USD
CategorySector
FocusHealth Care
Development LevelDeveloped Markets
RegionNorth America

Fund Statistics

Assets Under Management$8.90 billion
Average Daily Volume$2.74 million
Discount/Premium-1.41%

ETF Expenses

Management Fee0.47%
Other Expenses0.00%
Total Expenses0.47%
Fee Waiver0.00%
Net Expenses0.47%

Administrator, Advisor and Custodian

AdministratorState Street Bank and Trust Company
AdvisorBlackRock Fund Advisors
CustodianState Street Bank and Trust Company
DistributorBlackRock Investments, LLC
Transfer AgentState Street Bank and Trust Company
Trustee
Lead Market MakerVirtu Financial

Geographic Exposure of iShares NASDAQ Biotechnology Index (NASDAQ:IBB)
Currency Exposure of iShares NASDAQ Biotechnology Index (NASDAQ:IBB)
Sector Exposure of iShares NASDAQ Biotechnology Index (NASDAQ:IBB)
Industry Exposure of iShares NASDAQ Biotechnology Index (NASDAQ:IBB)

iShares NASDAQ Biotechnology Index (NASDAQ:IBB) Frequently Asked Questions

What is iShares NASDAQ Biotechnology Index's stock symbol?

iShares NASDAQ Biotechnology Index trades on the NASDAQ under the ticker symbol "IBB."

How often does iShares NASDAQ Biotechnology Index pay dividends? What is the dividend yield for iShares NASDAQ Biotechnology Index?

iShares NASDAQ Biotechnology Index declared a quarterly dividend on Thursday, December 21st. Shareholders of record on Friday, December 22nd will be given a dividend of $0.125 per share on Thursday, December 28th. This represents a $0.50 dividend on an annualized basis and a yield of 0.45%. The ex-dividend date is Thursday, December 21st. This is an increase from iShares NASDAQ Biotechnology Index's previous quarterly dividend of $0.04. View iShares NASDAQ Biotechnology Index's Dividend History.

When did iShares NASDAQ Biotechnology Index's stock split? How did iShares NASDAQ Biotechnology Index's stock split work?

iShares NASDAQ Biotechnology Index shares split on Friday, December 1st 2017. The 3-1 split was announced on Tuesday, November 7th 2017. The newly minted shares were issued to shareholders after the closing bell on Thursday, November 30th 2017. An investor that had 100 shares of iShares NASDAQ Biotechnology Index stock prior to the split would have 300 shares after the split.

Who are some of iShares NASDAQ Biotechnology Index's key competitors?

Who are iShares NASDAQ Biotechnology Index's key executives?

iShares NASDAQ Biotechnology Index's management team includes the folowing people:
  • George G. C. Parker Ph.D., Independent Chairman of the Board of Trustees
  • Michael Arthur Latham, President, Trustee
  • Jack Gee, Chief Financial Officer, Treasurer
  • Geoffrey D. Flynn, Chief Operating Officer, Executive Vice President
  • , Bio & Compensation - 
  • Amy Schioldager, Executive Vice President
  • Ira P. Shapiro, Vice President, Chief Legal Officer
  • Matt Tucker, Vice President
  • , Bio & Compensation - 
  • Eilleen M. Clavere, Secretary
  • Cecilia H. Herbert, Independent Trustee
  • Charles A. Hurty, Independent Trustee

Has iShares NASDAQ Biotechnology Index been receiving favorable news coverage?

Headlines about IBB stock have been trending somewhat positive this week, according to Accern Sentiment Analysis. Accern identifies negative and positive news coverage by analyzing more than 20 million news and blog sources. Accern ranks coverage of companies on a scale of negative one to one, with scores closest to one being the most favorable. iShares NASDAQ Biotechnology Index earned a media sentiment score of 0.11 on Accern's scale. They also assigned news headlines about the financial services provider an impact score of 48.19 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the company's share price in the immediate future.

Who are iShares NASDAQ Biotechnology Index's major shareholders?

iShares NASDAQ Biotechnology Index's stock is owned by many different of institutional and retail investors. Top institutional shareholders include Natixis (1.38%), Royal Bank of Canada (1.07%), Commerce Bank (0.97%), Clal Insurance Enterprises Holdings Ltd (0.91%), PNC Financial Services Group Inc. (0.79%) and LPL Financial LLC (0.61%). View Institutional Ownership Trends for iShares NASDAQ Biotechnology Index.

Which major investors are selling iShares NASDAQ Biotechnology Index stock?

IBB stock was sold by a variety of institutional investors in the last quarter, including Clal Insurance Enterprises Holdings Ltd, Psagot Investment House Ltd., BB&T Securities LLC, NF Trinity Capital Hong Kong Ltd, The Manufacturers Life Insurance Company , PNC Financial Services Group Inc., Blair William & Co. IL and Analyst IMS Investment Management Services Ltd.. View Insider Buying and Selling for iShares NASDAQ Biotechnology Index.

Which major investors are buying iShares NASDAQ Biotechnology Index stock?

IBB stock was bought by a variety of institutional investors in the last quarter, including Natixis, State of Tennessee Treasury Department, First Republic Investment Management Inc., Commerzbank Aktiengesellschaft FI, LPL Financial LLC, Graham Capital Management L.P., Cheyne Capital Management UK LLP and Timber Hill LLC. View Insider Buying and Selling for iShares NASDAQ Biotechnology Index.

How do I buy shares of iShares NASDAQ Biotechnology Index?

Shares of IBB can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is iShares NASDAQ Biotechnology Index's stock price today?

One share of IBB stock can currently be purchased for approximately $112.23.

How big of a company is iShares NASDAQ Biotechnology Index?

iShares NASDAQ Biotechnology Index has a market capitalization of $9.17 billion.


MarketBeat Community Rating for iShares NASDAQ Biotechnology Index (IBB)

Community Ranking:  2.5 out of 5 (star star half star)
Outperform Votes:  75 (Vote Outperform)
Underperform Votes:  75 (Vote Underperform)
Total Votes:  150
MarketBeat's community ratings are surveys of what our community members think about iShares NASDAQ Biotechnology Index and other stocks. Vote "Outperform" if you believe IBB will outperform the S&P 500 over the long term. Vote "Underperform" if you believe IBB will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 6/22/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.